Spectral Med Inc faced a challenging session on the TSX, reflecting investor caution.
Spectral Med Inc (EDT.TO) saw its stock price decline by 3.57% in yesterday's trading session, closing at CA$1.35. This drop comes amidst limited recent news and ongoing investor sentiment regarding the company's future prospects.
Advertisement
Spectral Med Inc
EDT.TO
EDT.TO
Spectral Med Inc
WealthAwesomeAdvertisement
Market cap
$407.85M
52W high
$1.84
52W low
$0.97
1W change
-1.42%
Beta
0.21
Analyst Price Targets
Based on analyst covering EDT
Wall Street analysts forecast EDT stock price to rise 126.6% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.15
+126.6% Upside
Current Price
C$1.39
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Advertisement
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on EDT's historical volatility
30-Day Vol
27.0%
Annualized
90-Day Vol
28.5%
Annualized
Trend (90d)
-6.0%
Annualized drift
90d Mean
C$1.36
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$1.38 | C$1.26 – C$1.51 |
| 60 trading days | C$1.37 | C$1.20 – C$1.56 |
| 90 trading days | C$1.36 | C$1.16 – C$1.60 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: Investors should stay alert as Spectral Med Inc navigates its commercialization efforts and market uncertainties.
-3.57%
Spectral Med Inc's stock fell by 3.57% yesterday, closing at CA$1.35, reflecting investor caution amid limited news.
Bull case
If Spectral can successfully advance its PMA application for PMX and show improved clinical outcomes, it may regain investor confidence and drive future growth.
Bear case
Continued uncertainty in the market and a lack of significant updates could further pressure Spectral's stock price, leading to more volatility.
Market Performance Overview
Advertisement
In yesterday's trading session, Spectral Med Inc's stock fell by 3.57%, closing at CA$1.35. This decline is notable given the company's recent activities, including its FDA PMA application filing for PMX, which has yet to translate into positive market sentiment.
Investor Sentiment
The drop in Spectral's stock price reflects a cautious approach from investors, likely influenced by the limited news flow and ongoing uncertainties surrounding the company's commercialization efforts. Without significant updates, investor confidence may continue to wane.
Looking Ahead
As Spectral Med Inc moves forward, it will be crucial for the company to provide clear updates on its clinical trials and regulatory progress. Positive developments could help restore investor confidence and stabilize the stock price.
Advertisement
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
